Related Experiment Video
Updated: May 9, 2026
08:21
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Aldosterone synthase inhibition in hypertension
1Cardiovascular Research Center, Landspitali the University Hospital of Iceland, IS-101, Reykjavik, Iceland, andersen@landspitali.is.
Current Hypertension Reports
|August 7, 2013
Summary
High blood pressure increases cardiovascular risks. New drugs inhibiting aldosterone production could offer better blood pressure control by preventing aldosterone breakthrough, a common issue with current treatments.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Hypertension is a major risk factor for stroke, coronary artery disease, and heart failure.
- Effective blood pressure control significantly reduces cardiovascular risk.
- The renin-angiotensin-aldosterone system (RAAS) plays a key role in blood pressure regulation, with aldosterone mediating salt reabsorption and having MR-independent effects.
Purpose of the Study:
- To address the limitations of current RAAS-targeting agents.
- To explore the potential of directly inhibiting aldosterone production.
- To investigate a novel approach for improved blood pressure management.
Main Methods:
- Review of existing pharmacological agents targeting the RAAS.
- Analysis of the feedback mechanisms within the RAAS cascade.
- Discussion of aldosterone breakthrough and its clinical implications.
Main Results:
- Current RAAS inhibitors can lead to increased renin and angiotensin II levels.
- Aldosterone breakthrough counteracts the long-term blood pressure-lowering effects of these agents.
- Direct aldosterone production inhibition offers a potential solution.
Conclusions:
- Developing agents that directly inhibit aldosterone production may be clinically useful.
- Such agents could offer superior blood pressure control by overcoming aldosterone breakthrough.
- This represents a promising new therapeutic strategy for hypertension.
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.